Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Arielle ElkriefBiagio RiccuitiJoao V AlessiTeng FeiHannah L KalvinJacklynn V EggerHira RizviRohit ThummalapalliGuiseppe LambertiAndrew PlodkowskiMatthew D HellmannMark G KrisMaria E ArcilaMarina K BaineCharles M RudinPiro LitoMarc LadanyiAdam J SchoenfeldGregory J RielyMark M AwadKathryn C ArbourPublished in: The oncologist (2023)
We define the outcomes to first-line chemo-immunotherapy in patients with KRASG12C, which provides a real-world benchmark for clinical trial design involving patients with KRASG12C mutations. Outcomes are poor in patients with specific molecular coalterations, highlighting the need to develop more effective frontline therapies.